FDA to alter biosimilar ‘suffix’ policy

The US Food and Drug Administration (FDA) yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

WIPR debuts Global In-House Elite 2026

26 March 2026 LSIPR sister title launches vetted list celebrating leading in-house counsel who demonstrate exceptional ability in managing their organisation's IP portfolio, legal team, and IP culture.

Biotechnology

mRNA litigation: Who’s winning, who’s filing, and what’s next

25 March 2026 As the world moves past the pandemic, a massive legal struggle over the future of mRNA technology is just hitting its stride. LSIPR visualises the litigation defining the next era.

Careers

Dechert boosts litigation bench with partner duo

25 March 2026 Two senior hires from a rival firm bring litigation expertise across life sciences and tech disputes.